RGNX News

Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, filed on Friday with the SEC to raise up to $69 million in an initial public offering. The Cambridge, MA-based company was founded in 2011. It plans to list on the Nasdaq under the symbol SYRS. Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing...read more

AveXis, an early-stage biotech developing gene therapies for rare neurological diseases, announced terms for its IPO on Monday. The Bannockburn, IL-based company plans to raise $85 million by offering 4.25 million shares at a price range of $19 to $21. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, AveXis would...read more

A bad start to the year only got worse this week as the S&P 500 fell another 2%. For the first time since October, the ninety-day returns swung negative to -0.6%. Just two weeks ago, that number stood at 17%. The VIX is up 48% year-to-date, closing Friday at 27. After 12 companies submitted their initial filings with the SEC in the first week of the year, just three...read more

Voyager Therapeutics, a gene therapy biotech targeting Parkinson's disease and other CNS disorders, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Voyager Therapeutics would command a fully diluted market value of $415 million....read more